CNS Treatment and Therapy Market Size and Share Forecast Outlook 2025 to 2035

The global CNS Treatment and Therapy Market is estimated to be valued at USD 136.3 billion in 2025 and is projected to reach USD 222.1 billion by 2035, registering a compound annual growth rate (CAGR) of 5.9% over the forecast period.

Metric Value
Market Size in 2025 USD 136.3 billion
Projected Market Size in 2035 USD 222.1 billion
CAGR (2025 to 2035) 5.9%

The CNS Treatment and Therapy Market is undergoing structural transformation as clinical innovation and regulatory pathways evolve to address unmet needs across neurodegenerative, psychiatric, and neurodevelopmental disorders. As of 2025, the market is being shaped by increased R&D funding in Alzheimer’s disease, major depressive disorder (MDD), multiple sclerosis (MS), Parkinson’s disease, and rare CNS pathologies such as Rett syndrome and Huntington’s disease.

Progress in disease-modifying therapies (DMTs), precision psychiatry, and neuroinflammation-targeted interventions is redefining the treatment landscape. This growth is further supported by expedited regulatory approvals, biomarker-guided drug development, and the integration of digital therapeutics into treatment protocols. Advances in blood-brain barrier (BBB) penetrant molecules, neurotrophic factor modulation, and neuroimmune axis manipulation are expanding therapeutic avenues that were previously inaccessible.

Key manufacturers driving the CNS Treatment and Therapy Market include Sanofi, Biogen, Eli Lilly, Otsuka Pharmaceutical, Neurocrine Biosciences, and Johnson & Johnson. These companies are actively expanding pipelines in neurodegeneration, schizophrenia, bipolar disorder, and epilepsy. In 2025, Sanofi that it has entered into an agreement to acquire Vigil Neuroscience, Inc. (“Vigil”), a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases.

In the official press briefing on May 22, 2025, Houman Ashrafian, Head of Research and Development, Sanofi, stated: “This acquisition is fully supporting Sanofi’s strategic focus on neurology and on advancing science and leveraging our expertise in immunology to solve areas of critical unmet need. TREM2 represents a compelling target at the intersection of immune dysregulation and neurodegeneration, particularly in people living with Alzheimer’s because they face devastating cognitive decline with limited treatment options.

Vigil’s expertise is complementary to our capabilities in neurology and reinforces our dedication to developing innovative medicines to improve people’s lives. Vigil’s team are a welcome addition, and we look forward to working with them and the patient community.”

Biogen continues to expand its Alzheimer’s pipeline beyond amyloid-beta, exploring tau-targeting and neuroprotective biologics. Meanwhile, Otsuka has initiated multi-center trials evaluating long-acting injectable formulations for schizophrenia and bipolar spectrum disorders. These developments reflect a broader industry pivot toward faster-acting, mechanism-diverse CNS therapies supported by predictive diagnostics and real-world validation frameworks.

Analyzing CNS Treatment and Therapy Market by Top Investment Segments

Biologics Leading the CNS Treatment and Therapy Market with Targeted Therapies

In 2025, biologics are estimated to hold 36.4% of the CNS Treatment and Therapy Market revenue, driven by a shift toward targeted, high-precision therapies. This segment’s dominance has been attributed to enhanced efficacy in addressing complex neuroinflammatory and neurodegenerative conditions where conventional small molecules have underperformed. The rise in monoclonal antibody (mAb) approvals for diseases such as multiple sclerosis, Alzheimer’s, and neuromyelitis optica has significantly contributed to the segment’s growth.

Additionally, supportive regulatory frameworks, particularly the FDA's expedited approval pathways, have facilitated faster market entry for CNS biologics. Further, advancements in blood-brain barrier penetration technologies and patient-tailored therapies have increased biologics' clinical success rate. Increased biologics R&D funding by major pharmaceutical players and the availability of biosimilars have also played a crucial role in expanding market reach. Demand has been further amplified by physicians' growing preference for long-acting injectable biologics due to improved patient adherence and reduced dosing frequency.

Antidepressants Leading Due to Rising Global Mental Health Burden

Antidepressants are projected to account for 26.4% of the CNS Treatment and Therapy Market in 2025, owing to the significant and growing burden of depression and anxiety-related disorders. The growth of this segment has been reinforced by rising awareness campaigns, reduced stigma around mental health, and greater screening and diagnosis rates in both developed and emerging economies. Second-generation antidepressants, including SSRIs and SNRIs, have gained clinical favour due to improved safety profiles and tolerability, which has increased patient adherence.

Moreover, the COVID-19 pandemic’s lasting psychological impact has triggered a surge in antidepressant prescriptions, particularly among younger populations. The launch of novel fast-acting antidepressants-especially NMDA receptor antagonists-and digital mental health solutions have further expanded treatment options. Health insurers have increasingly included antidepressants in reimbursement lists, improving access across varied socioeconomic groups. Together, these factors have sustained antidepressants as the leading drug class within the CNS therapeutics landscape.

Neurovascular Disorders Driving Market Dominance

In 2025, neurovascular disorders are expected to hold 18.7% revenue share in the CNS Treatment and Therapy Market, primarily due to the high global incidence and burden of conditions such as stroke, cerebral aneurysms, and vascular dementia. This segment’s growth has been influenced by aging demographics, a rise in hypertension and diabetes prevalence, and the increasing availability of advanced neurointerventional therapies. Market momentum has also been supported by technological improvements in clot retrieval devices, thrombolytic, and cerebral protection systems.

A paradigm shift toward early intervention and integrated stroke care in hospitals has expanded access to therapies, leading to favourable patient outcomes. Moreover, neurovascular treatment protocols have been integrated into national stroke care programs, further accelerating market expansion. The involvement of multidisciplinary stroke teams and real-time imaging tools in tertiary care centers has increased treatment uptake, consolidating neurovascular disorders as the largest segment within the CNS therapeutic market.

Hospital-Based Pharmacies Leading Access Points due to Centralized Dispensing

Hospital-based pharmacies are projected to hold 43.1% of the CNS therapy market share in 2025, attributed to the centralized dispensing of high-risk CNS drugs requiring clinical supervision. These pharmacies have been preferred due to their integration with neurologists and psychiatrists, facilitating on-site prescribing of specialized biologics, antipsychotics, and intrathecal medications. CNS disorders such as acute psychosis, stroke, and epilepsy often require immediate intervention, making hospital pharmacies the most reliable and efficient distribution channel.

The growth of this segment has also been driven by government investments in hospital infrastructure and the co-location of specialty care services. Enhanced inventory control, adherence monitoring, and pharmacist-led patient education programs have further solidified hospital pharmacies' position. Moreover, stringent regulations around the dispensation of certain CNS medications-especially controlled substances-have led to a reliance on hospital-based systems to ensure compliance and mitigate misuse, supporting their continued market leadership.

Regional Landscape Analysis

North America leads the CNS Treatment and Therapy Market, driven by strong clinical infrastructure, regulatory flexibility, and capital influx into neuroscience R&D. The USA accounts for a majority of global CNS drug approvals, supported by the FDA’s breakthrough therapy designations and priority reviews for neurodegenerative and psychiatric drugs. The NIH’s BRAIN Initiative and ARPA-H funding have catalysed translational research in neural circuit modulation and digital biomarkers.

Private equity is also funnelling investments into psychiatric start-up’s deploying psychedelic compounds, digital therapeutics, and closed-loop brain stimulation. Canada’s growing role in neuroinflammation and early-phase Parkinson’s trials-supported by CIHR funding-is contributing to the region’s expanding therapeutic footprint. Strategic partnerships between pharma companies and AI-led biotechs are fast-tracking molecule discovery and behavioural phenotyping platforms, reinforcing the region’s leadership in CNS therapy innovation.

Europe’s CNS therapy market is evolving through coordinated regulatory science, public health prioritization, and academic excellence. The EMA’s adaptive pathways program and the EU-funded “Neurodegeneration Platform” are advancing orphan drug and neuroimmunology-based approvals.

Germany and the Netherlands are leading in integrating digital therapeutics for ADHD and depression into public insurance schemes, while France and Italy are scaling university spinouts for Parkinson’s and epilepsy therapies. The region’s early investments in digital biomarkers, combined with collaborative neuroimaging consortia, are enhancing precision in CNS clinical trials. As Europe pursues greater sovereignty in biologics manufacturing and neuropharma innovation, the CNS market is poised for high-value expansion, especially in rare and treatment-resistant indications.

Challenges and Opportunities

Challenges

High Drug Development Costs and Regulatory Hurdles

High expenditure requirements for CNs treatment and therapy are another factor for the growth of this market sector and in addition, drug combine dares, clinical tests and regulatory filtration are key problems for CNS treatments and likewise therapy segment. Drugs for central nervous system (CNS) disorders such as Alzheimer's, Parkinson's, epilepsy, depression and others require extensive research and testing to determine their efficacy and safety.

Moreover, strict regulations by agencies such as the FDA and EMA, in addition to the challenge in CNS drug mechanisms, further lead to prolonged approval timelines and high failure rates. By focusing on these aspects and embracing new technologies, pharmaceutical companies can overcome these challenges and ultimately improve the success rates and reduce the costs associated with drug development.

Limited Treatment Efficacy and Side Effects

While CNS therapies have progressed, many treatments available do not have high efficacy, do not provide prolonged relief, or result in considerable side-effects. The management of conditions such as multiple sclerosis, schizophrenia, and chronic pain are often lifelong processes, so the development of treatments that improve patient quality of life becomes paramount. The blood-brain barrier (BBB) also presents another challenge in terms of drug delivery, limiting the effectiveness of many CNS medications. How to do this is to concentrate on the development of targeted, drug delivery systems, innovative biologics, and gene therapies that can be clinically223-used to improve treatment outcomes while limiting adverse effects.

Opportunities

Growth in Neuromodulation and Personalized Medicine

Additionally, neuromodulation techniques are an emerging opportunity area with therapies involving deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), and vagus nerve stimulation (VNS) emerging as key therapies. Offering these patients an alternative to their drug resistant CNS disorders, these therapies are minimally invasive or non-invasive and minimize the use of pharmaceuticals.

New technologies in personalized medicine, including pharmacogenomics and AI-driven diagnostics, enable the development of customized treatment regimens according to an individual’s genetic and neuropathological disposition. Innovations like AI-enabled patient tracking systems, wearable bio-sensors, and neurological stimulation devices will give companies a competitive advantage in the growing CNS treatment space.

Advancements in Biologics, Gene Therapy, and Regenerative Medicine

The CNS treatment and therapy market is being transformed as novel biologics, gene therapy, and stem cell therapies emerge. These new therapeutic modalities are being suggested to target neuronal structures and recover chronic neurodegeneration and therefore, produce disease-modifying effects in neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), spinal cord injury as well as neurodegenerative diseases rather than just alleviating symptoms.

Moreover, novel CRISPR gene editing technology, neurotrophic factor therapies, and processes that make induced pluripotent stem cells (iPSCs) are opening up new frontiers in regenerative medicine.The next generation of CNS treatment innovations will be powered by companies that harness these advanced technologies, collaborate with academic institutions, and obtain regulatory fast-track approvals.

CNS Treatment and Therapy Market Dynamics and Future Trends 2025 to 2035 Between 2020 and 2024, there were remarkable advances in the CNS treatment and therapy sector, focusing on areas like digital therapeutics, artificial intelligence-driven drug discovery, and neuromodulation therapies.

But instead, high prices and R&D costs or drug development failures, as well as accessibility, remained ongoing threats. And biopharma companies stepped up, developing artificial intelligence tools for clinical trials, repurposing existing pharmaceuticals and improving collaboration between biotech companies and research institutes to speed up innovation.

For 2025 to 2035, the market will see transformative advancements in precision neurology, brain-computer interfaces (BCIs), and regenerative CNS therapies. Innovations like AI-driven cognitive assessment tools, wearable neuro monitors for cognition, and neuroimaging will enable early diagnosis and treatment of disease.

Elsewhere, uses of blockchain in protecting clinical data, telemedicine in delivering neurological services remotely, and nanotechnology for drug delivery will transform CNS treatment paradigms. The next wave of CNS innovations will be driven in large part by companies that embrace digital transformation, regenerative medicine, and patient-centric care models.

Country-wise Outlook- CNS treatment and therapy market

United States

Strong healthcare infrastructure, higher prevalence of CNS disorders and advancements in drug development are primely responsible for the USA being the major contributor towards CNS treatment and therapy market. The market growth is attributed due to the presence of multinational pharmaceutical organizations and ongoing work in neurodegenerative diseases.

The market also anticipates the increase in demand for biologics and gene therapies as innovative CNS therapies, the growing role of AI in drug discovery, and precision medicine. Moreover, rising acceptance of digital therapeutics, neurostimulation devices, and individualized treatment strategies are improving treatment outcome.

Companies are also concentrating on new small-molecule drugs and targeted therapies for diseases like Alzheimer’s, Parkinson’s and multiple sclerosis. In the USA, the market is further driven by government funding for mental health research and CNS disorder treatment.

Country CAGR (2025 to 2035)
USA 5.3%

United Kingdom

This is attributed to the major investments in neuroscience research, rising demand for mental health solutions, and improved accessibility to novel therapeutics are driving the market growth of CNS in the UK. Also driving demand is the emphasis on early diagnosis and intervention.

Government initiatives supporting mental health awareness are expected to aid the market growth along with advancements in neuroimaging and biomarker-based diagnostics. Stem Cell Therapy CNS/Germline Tailored Therapies: Modulating CNS Disorders: The data also showed burgeoning interest in disease-modifying treatments, stem cell therapy, and regenerative medicine addressing CNS disorders. Other companies are also developing the use of AI powered designs for clinical trials to staff on to drug approvals and improve efficacy of the treatments.

The growing trend of telemedicine and remote patient management for neurological diseases is also fueling the market growth in the UK. Moreover, the emergence of both personalized medicine and cognitive rehabilitation therapies is enhancing patient management.

Country CAGR (2025 to 2035)
UK 4.8%

European Union

The European CNS therapies and treatment market is being ruled by Germany, France, and Italy, which has a well-established healthcare infrastructure, steady government investment in neuroscience support, and rising prevalence of targeted neurological therapies.

The aggressive growth in the European CNS market is due to the research focus on CNS therapies along with an interest in neuropharmacology. The use of AI-powered diagnostics, efficient neurostimulation techniques, and biomarker-based drug development is also making therapies more effective.

This is further propelling the market growth attributed to increasing demand for non-invasive brain stimulation, cognitive behavioral therapy, and digital health solutions for CNS disorders. The growing number of clinical research partnerships, alongside the launch of innovative biosimilars for neurodegenerative conditions, are driving the uptake of CNS therapies throughout the EU. Moreover, regulatory incentives around orphan drugs and rare neurological diseases are speeding up drug development efforts.

Country CAGR (2025 to 2035)
European Union (EU) 4.9%

Japan

The Japan CNS treatment and therapy market is growing due to the aging population, increased prevalence of neurodegenerative disorders in the country, and advancements in drug discovery. Increasing emphasis on neuroprotection and intervention in the early stages is expected to propel market expansion.

Godoy covered how the nation’s focus on high-tech research and the coupling of AI-driven drug discovery and wearable neurological monitoring gadgets drives innovation in the nation. Additionally, solid government backing for dementia and Parkinson’s disease research, in tandem with rising investment for gene and cell therapies, is providing impetus to work on next-generation CNS treatments.

Additionally, the increasing prevalence of non-invasive brain stimulation, cognitive training program, and mindfulness-based therapies is propelling the market growth in Japan healthcare sector. Further, partnerships between academic institutions and biotech companies are bolstering research on the management of neurodegenerative diseases.

Country CAGR (2025 to 2035)
Japan 5.1%

South Korea

The market for CNS treatment and therapy can also flourish in South Korea, owing to the rising awareness regarding neurological disorders, increasing investments in the mental health sector, and increasing demand for advanced therapeutics.

The market is expanding due to supportive government regulations for brain health research and increasing implementation of digital therapeutics. Moreover, the national focus on increasing the efficiency of treatment through AI-based, drug discovery, neurotechnology and brain-computer interface research is bolstering competitiveness.

Additionally, the rising need for novel CNS therapies in psychiatry, neurodegenerative diseases, and sleep disorders is driving market adoption. Time autonomy of patients' performance can be recorded and used in the design of clinical trials based on artificial intelligence.

The increasing number of government-backed mental health campaigns and establishment of neuroscience research institutes in South Korea are also propelling the demand for CNS treatments and therapies.

Country CAGR (2025 to 2035)
South Korea 5.2%

Competitive Outlook

The CNS Treatment and Therapy Market is driven by the rising prevalence of neurological disorders, fast-paced development of biotechnology, and increasing industry-wide investment in drug observance.

To address this issue, organizations focused on enhancing patient outcomes are increasingly leveraging biologics, targeted therapies and neurostimulation devices. This encompasses AI driven drug discovery, precision medicine, and discovery of new therapeutic entities for neurodegenerative diseases, psychiatric diseases and neurovascular diseases.

Cns Treatment And Therapy Market Analysis By Company

Key Players

  • Roche Holding AG
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • AbbVie Inc
  • AstraZeneca plc

CNS Treatment and Therapy Market Segmentation

By Drug:

  • Biologics
  • Non Biologics

By Drug Class:

  • Antidepressant
  • Analgesics
  • Immunomodulators
  • Interferons
  • Decarboxylase Inhibitors
  • Others

By Disease:

  • Neurovascular Disease
  • Degenerative Disease
  • Infectious Disease
  • Mental Health
  • Others

By Distribution Channel:

  • Hospital Based Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Eastern Europe
  • Western Europe
  • Middle East & Africa

Table of Content

  1. Executive Summary
  2. Industry Introduction, including Taxonomy and Market Definition
  3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
  4. Global Market Demand Analysis 2020 to 2024 and Forecast 2025 to 2035, including Historical Analysis and Future Projections
  5. Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035
    • By Drug
    • By Drug Class
    • By Disease
    • By Distribution Channel
  6. Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Drug
    • Biologics
    • Non Biologics
  7. Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Drug Class
    • Antidepressant
    • Analgesics
    • Immunomodulators
    • Interferons
    • Decarboxylase Inhibitors
    • Others
  8. Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Disease
    • Neurovascular Disease
    • Degenerative Disease
    • Infectious Disease
    • Mental Health
    • Others
  9. Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Distribution Channel
    • Hospital Based Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  10. Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Region
    • North America
    • Latin America
    • East Asia
    • South Asia & Pacific
    • Eastern Europe
    • Western Europe
    • Middle East & Africa
  11. North America Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
  12. Latin America Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
  13. East Asia Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
  14. South Asia & Pacific Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
  15. Eastern Europe Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
  16. Western Europe Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
  17. Middle East & Africa Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
  18. Sales Forecast 2025 to 2035 by Drug, Drug Class, Disease, and Distribution Channel for 30 Countries
  19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
  20. Company Profile
    • AbbVie Inc.
    • Alkermes Plc
    • Allergan Plc
    • AstraZeneca Plc
    • BIAL Group
    • Bristol-Myers Squibb
    • Eisai Co., Ltd.
    • Endo Pharmaceuticals
    • Eli Lilly and Co.
    • F. Hoffmann-La Roche Ltd.

List of Tables

  • Table 01: Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Drug
  • Table 02: Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Drug Class
  • Table 03: Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Disease
  • Table 04: Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Distribution Channel
  • Table 05: Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Region
  • Table 06: North America Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Country
  • Table 07: North America Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Drug
  • Table 08: North America Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Drug Class
  • Table 09: North America Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Disease
  • Table 10: North America Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Distribution Channel
  • Table 11: Latin America Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Country
  • Table 12: Latin America Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Drug
  • Table 13: Latin America Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Drug Class
  • Table 14: Latin America Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Disease
  • Table 15: Latin America Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Distribution Channel
  • Table 16: Europe Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Country
  • Table 17: Europe Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Drug
  • Table 18: Europe Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Drug Class
  • Table 19: Europe Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Disease
  • Table 20: Europe Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Distribution Channel
  • Table 21: East Asia Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Country
  • Table 22: East Asia Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Drug
  • Table 23: East Asia Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Drug Class
  • Table 24: East Asia Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Disease
  • Table 25: East Asia Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Distribution Channel
  • Table 26: South Asia Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Country
  • Table 27: South Asia Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Drug
  • Table 28: South Asia Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Drug Class
  • Table 29: South Asia Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Disease
  • Table 30: South Asia Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Distribution Channel
  • Table 31: Oceania Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Country
  • Table 32: Oceania Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Drug
  • Table 33: Oceania Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Drug Class
  • Table 34: Oceania Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Disease
  • Table 35: Oceania Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Distribution Channel
  • Table 36: Middle East & Africa Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Country
  • Table 37: Middle East & Africa Market Value (USD Million) Analysis 2020 to 2024 and Forecast 2025 to 2035, by Drug
  • Table 38: Middle East & Africa Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Drug Class
  • Table 39: Middle East & Africa Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Disease
  • Table 40: Middle East & Africa Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Distribution Channel

List of Figures

  • Figure 01: Global Market Value (USD Million) Analysis, 2020 to 2024
  • Figure 02: Global Market Forecast & Y-o-Y Growth, 2025 to 2035
  • Figure 03: Global Market Absolute $ Opportunity (USD Million) Analysis, 2025 to 2035
  • Figure 04: Global Market Value Share (%) Analysis 2025 and 2035, by Drug
  • Figure 05: Global Market Y-o-Y Growth (%) Analysis 2025 to 2035, by Drug
  • Figure 06: Global Market Attractiveness Analysis 2025 to 2035, by Drug
  • Figure 07: Global Market Value Share (%) Analysis 2025 and 2035, by Drug Class
  • Figure 08: Global Market Y-o-Y Growth (%) Analysis 2025 to 2035, by Drug Class
  • Figure 09: Global Market Attractiveness Analysis 2025 to 2035, by Drug Class
  • Figure 10: Global Market Value Share (%) Analysis 2025 and 2035, by Disease
  • Figure 11: Global Market Y-o-Y Growth (%) Analysis 2025 to 2035, by Disease
  • Figure 12: Global Market Attractiveness Analysis 2025 to 2035, by Disease
  • Figure 13: Global Market Value Share (%) Analysis 2025 and 2035, by Distribution Channel
  • Figure 14: Global Market Y-o-Y Growth (%) Analysis 2025 to 2035, by Distribution Channel
  • Figure 15: Global Market Attractiveness Analysis 2025 to 2035, by Distribution Channel
  • Figure 16: Global Market Value Share (%) Analysis 2025 and 2035, by Region
  • Figure 17: Global Market Y-o-Y Growth (%) Analysis 2025 to 2035, by Region
  • Figure 18: Global Market Attractiveness Analysis 2025 to 2035, by Region
  • Figure 19: North America Market Value (USD Million) Analysis, 2020 to 2024
  • Figure 20: North America Market Value (USD Million) Forecast, 2025 to 2035
  • Figure 21: North America Market Value Share, by Drug (2025 E)
  • Figure 22: North America Market Value Share, by Drug Class (2025 E)
  • Figure 23: North America Market Value Share, by Disease (2025 E)
  • Figure 24: North America Market Value Share, by Distribution Channel (2025 E)
  • Figure 25: North America Market Value Share, by Country (2025 E)
  • Figure 26: North America Market Attractiveness Analysis by Drug, 2025 to 2035
  • Figure 27: North America Market Attractiveness Analysis by Drug Class, 2025 to 2035
  • Figure 28: North America Market Attractiveness Analysis by Disease, 2025 to 2035
  • Figure 29: North America Market Attractiveness Analysis by Distribution Channel, 2025 to 2035
  • Figure 30: North America Market Attractiveness Analysis by Country, 2025 to 2035
  • Figure 31: USA Market Value Proportion Analysis, 2024
  • Figure 32: Global Vs. USA Growth Comparison
  • Figure 33: USA Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 34: USA Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 35: USA Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 36: USA Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 37: Canada Market Value Proportion Analysis, 2024
  • Figure 38: Global Vs. Canada. Growth Comparison
  • Figure 39: Canada Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 40: Canada Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 41: Canada Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 42: Canada Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 43: Latin America Market Value (USD Million) Analysis, 2020 to 2024
  • Figure 44: Latin America Market Value (USD Million) Forecast, 2025 to 2035
  • Figure 45: Latin America Market Value Share, by Drug (2025 E)
  • Figure 46: Latin America Market Value Share, by Drug Class (2025 E)
  • Figure 47: Latin America Market Value Share, by Disease (2025 E)
  • Figure 48: Latin America Market Value Share, by Distribution Channel (2025 E)
  • Figure 49: Latin America Market Value Share, by Country (2025 E)
  • Figure 50: Latin America Market Attractiveness Analysis by Drug, 2025 to 2035
  • Figure 51: Latin America Market Attractiveness Analysis by Drug Class, 2025 to 2035
  • Figure 52: Latin America Market Attractiveness Analysis by Disease, 2025 to 2035
  • Figure 53: Latin America Market Attractiveness Analysis by Distribution Channel, 2025 to 2035
  • Figure 54: Latin America Market Attractiveness Analysis by Country, 2025 to 2035
  • Figure 55: Mexico Market Value Proportion Analysis, 2024
  • Figure 56: Global Vs Mexico Growth Comparison
  • Figure 57: Mexico Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 58: Mexico Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 59: Mexico Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 60: Mexico Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 61: Brazil Market Value Proportion Analysis, 2024
  • Figure 62: Global Vs. Brazil. Growth Comparison
  • Figure 63: Brazil Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 64: Brazil Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 65: Brazil Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 66: Brazil Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 67: Argentina Market Value Proportion Analysis, 2024
  • Figure 68: Global Vs Argentina Growth Comparison
  • Figure 69: Argentina Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 70: Argentina Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 71: Argentina Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 72: Argentina Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 73: Europe Market Value (USD Million) Analysis, 2020 to 2024
  • Figure 74: Europe Market Value (USD Million) Forecast, 2025 to 2035
  • Figure 75: Europe Market Value Share, by Drug (2025 E)
  • Figure 76: Europe Market Value Share, by Drug Class (2025 E)
  • Figure 77: Europe Market Value Share, by Disease (2025 E)
  • Figure 78: Europe Market Value Share, by Distribution Channel (2025 E)
  • Figure 79: Europe Market Value Share, by Country (2025 E)
  • Figure 80: Europe Market Attractiveness Analysis by Drug, 2025 to 2035
  • Figure 81: Europe Market Attractiveness Analysis by Drug Class, 2025 to 2035
  • Figure 82: Europe Market Attractiveness Analysis by Disease, 2025 to 2035
  • Figure 83: Europe Market Attractiveness Analysis by Distribution Channel, 2025 to 2035
  • Figure 84: Europe Market Attractiveness Analysis by Country, 2025 to 2035
  • Figure 85: UK Market Value Proportion Analysis, 2024
  • Figure 86: Global Vs. UK Growth Comparison
  • Figure 87: UK Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 88: UK Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 89: UK Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 90: UK Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 91: Germany Market Value Proportion Analysis, 2024
  • Figure 92: Global Vs. Germany Growth Comparison
  • Figure 93: Germany Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 94: Germany Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 95: Germany Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 96: Germany Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 97: Italy Market Value Proportion Analysis, 2024
  • Figure 98: Global Vs. Italy Growth Comparison
  • Figure 99: Italy Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 100: Italy Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 101: Italy Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 102: Italy Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 103: France Market Value Proportion Analysis, 2024
  • Figure 104: Global Vs France Growth Comparison
  • Figure 105: France Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 106: France Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 107: France Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 108: France Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 109: Spain Market Value Proportion Analysis, 2024
  • Figure 110: Global Vs Spain Growth Comparison
  • Figure 111: Spain Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 112: Spain Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 113: Spain Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 114: Spain Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 115: Russia Market Value Proportion Analysis, 2024
  • Figure 116: Global Vs Russia Growth Comparison
  • Figure 117: Russia Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 118: Russia Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 119: Russia Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 120: Russia Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 121: BENELUX Market Value Proportion Analysis, 2024
  • Figure 122: Global Vs BENELUX Growth Comparison
  • Figure 123: BENELUX Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 124: BENELUX Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 125: BENELUX Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 126: BENELUX Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 127: East Asia Market Value (USD Million) Analysis, 2020 to 2024
  • Figure 128: East Asia Market Value (USD Million) Forecast, 2025 to 2035
  • Figure 129: East Asia Market Value Share, by Drug (2025 E)
  • Figure 130: East Asia Market Value Share, by Drug Class (2025 E)
  • Figure 131: East Asia Market Value Share, by Disease (2025 E)
  • Figure 132: East Asia Market Value Share, by Distribution Channel (2025 E)
  • Figure 133: East Asia Market Value Share, by Country (2025 E)
  • Figure 134: East Asia Market Attractiveness Analysis by Drug, 2025 to 2035
  • Figure 135: East Asia Market Attractiveness Analysis by Drug Class, 2025 to 2035
  • Figure 136: East Asia Market Attractiveness Analysis by Disease, 2025 to 2035
  • Figure 137: East Asia Market Attractiveness Analysis by Distribution Channel, 2025 to 2035
  • Figure 138: East Asia Market Attractiveness Analysis by Country, 2025 to 2035
  • Figure 139: China Market Value Proportion Analysis, 2024
  • Figure 140: Global Vs. China Growth Comparison
  • Figure 141: China Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 142: China Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 143: China Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 144: China Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 145: Japan Market Value Proportion Analysis, 2024
  • Figure 146: Global Vs. Japan Growth Comparison
  • Figure 147: Japan Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 148: Japan Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 149: Japan Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 150: Japan Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 151: South Korea Market Value Proportion Analysis, 2024
  • Figure 152: Global Vs South Korea Growth Comparison
  • Figure 153: South Korea Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 154: South Korea Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 155: South Korea Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 156: South Korea Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 157: South Asia Market Value (USD Million) Analysis, 2020 to 2024
  • Figure 158: South Asia Market Value (USD Million) Forecast, 2025 to 2035
  • Figure 159: South Asia Market Value Share, by Drug (2025 E)
  • Figure 160: South Asia Market Value Share, by Drug Class (2025 E)
  • Figure 161: South Asia Market Value Share, by Disease (2025 E)
  • Figure 162: South Asia Market Value Share, by Distribution Channel (2025 E)
  • Figure 163: South Asia Market Value Share, by Country (2025 E)
  • Figure 164: South Asia Market Attractiveness Analysis by Drug, 2025 to 2035
  • Figure 165: South Asia Market Attractiveness Analysis by Drug Class, 2025 to 2035
  • Figure 166: South Asia Market Attractiveness Analysis by Disease, 2025 to 2035
  • Figure 167: South Asia Market Attractiveness Analysis by Distribution Channel, 2025 to 2035
  • Figure 168: South Asia Market Attractiveness Analysis by Country, 2025 to 2035
  • Figure 169: India Market Value Proportion Analysis, 2024
  • Figure 170: Global Vs. India Growth Comparison
  • Figure 171: India Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 172: India Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 173: India Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 174: India Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 175: Indonesia Market Value Proportion Analysis, 2024
  • Figure 176: Global Vs. Indonesia Growth Comparison
  • Figure 177: Indonesia Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 178: Indonesia Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 179: Indonesia Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 180: Indonesia Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 181: Malaysia Market Value Proportion Analysis, 2024
  • Figure 182: Global Vs. Malaysia Growth Comparison
  • Figure 183: Malaysia Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 184: Malaysia Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 185: Malaysia Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 186: Malaysia Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 187: Thailand Market Value Proportion Analysis, 2024
  • Figure 188: Global Vs. Thailand Growth Comparison
  • Figure 189: Thailand Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 190: Thailand Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 191: Thailand Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 192: Thailand Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 193: Oceania Market Value (USD Million) Analysis, 2020 to 2024
  • Figure 194: Oceania Market Value (USD Million) Forecast, 2025 to 2035
  • Figure 195: Oceania Market Value Share, by Drug (2025 E)
  • Figure 196: Oceania Market Value Share, by Drug Class (2025 E)
  • Figure 197: Oceania Market Value Share, by Disease (2025 E)
  • Figure 198: Oceania Market Value Share, by Distribution Channel (2025 E)
  • Figure 199: Oceania Market Value Share, by Country (2025 E)
  • Figure 200: Oceania Market Attractiveness Analysis by Drug, 2025 to 2035
  • Figure 201: Oceania Market Attractiveness Analysis by Drug Class, 2025 to 2035
  • Figure 202: Oceania Market Attractiveness Analysis by Disease, 2025 to 2035
  • Figure 203: Oceania Market Attractiveness Analysis by Distribution Channel, 2025 to 2035
  • Figure 204: Oceania Market Attractiveness Analysis by Country, 2025 to 2035
  • Figure 205: Australia Market Value Proportion Analysis, 2024
  • Figure 206: Global Vs. Australia Growth Comparison
  • Figure 207: Australia Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 208: Australia Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 209: Australia Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 210: Australia Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 211: New Zealand Market Value Proportion Analysis, 2024
  • Figure 212: Global Vs New Zealand Growth Comparison
  • Figure 213: New Zealand Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 214: New Zealand Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 215: New Zealand Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 216: New Zealand Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 217: Middle East & Africa Market Value (USD Million) Analysis, 2020 to 2024
  • Figure 218: Middle East & Africa Market Value (USD Million) Forecast, 2025 to 2035
  • Figure 219: Middle East & Africa Market Value Share, by Drug (2025 E)
  • Figure 220: Middle East & Africa Market Value Share, by Drug Class (2025 E)
  • Figure 221: Middle East & Africa Market Value Share, by Disease (2025 E)
  • Figure 222: Middle East & Africa Market Value Share, by Distribution Channel (2025 E)
  • Figure 223: Middle East & Africa Market Value Share, by Country (2025 E)
  • Figure 224: Middle East & Africa Market Attractiveness Analysis by Drug, 2025 to 2035
  • Figure 225: Middle East & Africa Market Attractiveness Analysis by Drug Class, 2025 to 2035
  • Figure 226: Middle East & Africa Market Attractiveness Analysis by Disease, 2025 to 2035
  • Figure 227: Middle East & Africa Market Attractiveness Analysis by Distribution Channel, 2025 to 2035
  • Figure 228: Middle East & Africa Market Attractiveness Analysis by Country, 2025 to 2035
  • Figure 229: GCC Countries Market Value Proportion Analysis, 2024
  • Figure 230: Global Vs GCC Countries Growth Comparison
  • Figure 231: GCC Countries Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 232: GCC Countries Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 233: GCC Countries Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 234: GCC Countries Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 235: Türkiye Market Value Proportion Analysis, 2024
  • Figure 236: Global Vs. Türkiye Growth Comparison
  • Figure 237: Türkiye Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 238: Türkiye Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 239: Türkiye Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 240: Türkiye Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 241: South Africa Market Value Proportion Analysis, 2024
  • Figure 242: Global Vs. South Africa Growth Comparison
  • Figure 243: South Africa Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 244: South Africa Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 245: South Africa Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 246: South Africa Market Share Analysis (%) by Distribution Channel, 2025 to 2035
  • Figure 247: North Africa Market Value Proportion Analysis, 2024
  • Figure 248: Global Vs North Africa Growth Comparison
  • Figure 249: North Africa Market Share Analysis (%) by Drug, 2025 to 2035
  • Figure 250: North Africa Market Share Analysis (%) by Drug Class, 2025 to 2035
  • Figure 251: North Africa Market Share Analysis (%) by Disease, 2025 to 2035
  • Figure 252: North Africa Market Share Analysis (%) by Distribution Channel, 2025 to 2035

Frequently Asked Questions

What was the overall size of the CNS treatment and therapy market in 2025?

The overall market size for CNS treatment and therapy market was USD 136.3 billion in 2025.

How big the Bio is based CNS treatment and therapy market expected in 2035?

The CNS treatment and therapy market expected to reach USD 222.1 billion in 2035.

What will drive the demand for CNS treatment and therapy market during the forecast period?

Factors such as the growing number of neurological disorders, growing aging population and advancements in drug delivery and neuro technology, rising investment in the treatment of mental health and the expanding access to innovative therapies for diseases such as Alzheimer’s, Parkinson’s disease, and epilepsy will promote the demand for CNS treatment and therapy market.

List the top 5 countries contributing CNS treatment and therapy market?

The top 5 countries which drives the development of CNS treatment and therapy market are USA, UK, Europe Union, Japan and South Korea.

Which segment in type is expected to lead CNS treatment and therapy market?

Biologics and non-biologics growth to command significant share over the assessment period.

Explore Similar Insights

Future Market Insights

CNS Treatment and Therapy Market